290 related articles for article (PubMed ID: 28864502)
1. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
Douros A; Yin H; Yu OHY; Filion KB; Azoulay L; Suissa S
Diabetes Care; 2017 Nov; 40(11):1506-1513. PubMed ID: 28864502
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic Heterogeneity and Risk of Severe Hypoglycemia with Concomitant Use of Sulfonylureas and DPP-4 Inhibitors: Population-Based Cohort Study.
Dimakos J; Cui Y; Platt RW; Renoux C; Filion KB; Douros A
Clin Pharmacol Ther; 2023 Sep; 114(3):712-720. PubMed ID: 37326010
[TBL] [Abstract][Full Text] [Related]
3. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study.
Filion KB; Douros A; Azoulay L; Yin H; Yu OH; Suissa S
Br J Clin Pharmacol; 2019 Oct; 85(10):2378-2389. PubMed ID: 31276600
[TBL] [Abstract][Full Text] [Related]
4. Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
Diabetes Res Clin Pract; 2015 Jan; 107(1):104-12. PubMed ID: 25458330
[TBL] [Abstract][Full Text] [Related]
5. Mortality risk among sulfonylureas: a systematic review and network meta-analysis.
Simpson SH; Lee J; Choi S; Vandermeer B; Abdelmoneim AS; Featherstone TR
Lancet Diabetes Endocrinol; 2015 Jan; 3(1):43-51. PubMed ID: 25466239
[TBL] [Abstract][Full Text] [Related]
6. Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.
Abdelmoneim AS; Eurich DT; Senthilselvan A; Qiu W; Simpson SH
Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1186-1195. PubMed ID: 27102581
[TBL] [Abstract][Full Text] [Related]
7. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.
Douros A; Dell'Aniello S; Yu OHY; Filion KB; Azoulay L; Suissa S
BMJ; 2018 Jul; 362():k2693. PubMed ID: 30021781
[TBL] [Abstract][Full Text] [Related]
8. HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.
Confederat L; Constantin S; Lupaşcu F; Pânzariu A; Hăncianu M; Profire L
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):579-84. PubMed ID: 26204670
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Mitochondrial Adenosine Triphosphate-Sensitive Potassium Channel High- vs Low-Affinity Sulfonylureas and Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With Metformin.
Wang MT; Pan HY; Huang YL; Wu LW; Wang PC; Hsu YJ; Lin TC; Lin C; Lai JH; Lee CH
JAMA Netw Open; 2022 Dec; 5(12):e2245854. PubMed ID: 36484988
[TBL] [Abstract][Full Text] [Related]
10. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure.
Andersson C; Gislason GH; Jørgensen CH; Hansen PR; Vaag A; Sørensen R; Mérie C; Olesen JB; Weeke P; Schmiegelow M; Norgaard ML; Køber L; Torp-Pedersen C
Diabetes Res Clin Pract; 2011 Oct; 94(1):119-25. PubMed ID: 21831467
[TBL] [Abstract][Full Text] [Related]
11. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
Abdelmoneim AS; Eurich DT; Gamble JM; Johnson JA; Seubert JM; Qiu W; Simpson SH
Diabetes Obes Metab; 2014 Jan; 16(1):22-9. PubMed ID: 23802997
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
[TBL] [Abstract][Full Text] [Related]
13. Rates of hypoglycemia in users of sulfonylureas.
van Staa T; Abenhaim L; Monette J
J Clin Epidemiol; 1997 Jun; 50(6):735-41. PubMed ID: 9250272
[TBL] [Abstract][Full Text] [Related]
14. Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study.
Douros A; Dell'Aniello S; Yu OHY; Suissa S
Diabetes Obes Metab; 2020 Feb; 22(2):254-262. PubMed ID: 31596043
[TBL] [Abstract][Full Text] [Related]
15. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.
Wheeler S; Moore K; Forsberg CW; Riley K; Floyd JS; Smith NL; Boyko EJ
Diabetologia; 2013 Sep; 56(9):1934-43. PubMed ID: 23797633
[TBL] [Abstract][Full Text] [Related]
16. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.
Yu O; Azoulay L; Yin H; Filion KB; Suissa S
Am J Med; 2018 Mar; 131(3):317.e11-317.e22. PubMed ID: 29032229
[TBL] [Abstract][Full Text] [Related]
17. Comparative safety of sulfonylureas among U.S. nursing home residents.
Zullo AR; Riester MR; Hayes KN; Munshi MN; Berry SD
J Am Geriatr Soc; 2023 Apr; 71(4):1047-1057. PubMed ID: 36495141
[TBL] [Abstract][Full Text] [Related]
18. Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus.
Cho EH; Han K; Kim B; Lee DH
Medicine (Baltimore); 2020 Jul; 99(29):e21236. PubMed ID: 32702900
[TBL] [Abstract][Full Text] [Related]
19. Association Between Specificity of Sulfonylureas to Cardiac Mitochondrial KATP Channels and the Risk of Major Adverse Cardiovascular Events in Type 2 Diabetes.
Wang MT; Huang YL; Lai JH; Lee CH; Wang PC; Pan HY; Lin C; Liou JT; Hsu YJ
Diabetes Care; 2022 May; 45(5):1276-1287. PubMed ID: 35294529
[TBL] [Abstract][Full Text] [Related]
20. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes.
Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Murff HJ; Elasy TA; Griffin MR
JAMA; 2014 Jun; 311(22):2288-96. PubMed ID: 24915260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
